Originally, it was used to treat patients with diabetes, but treatment is now expanding to individuals who are overweight or are dealing with obesity
Still, its a good potential customer acquisition strategy for Novo Nordisk, Leventhal said, because its tapping into a retailer that has a very, very loyal and large customer base. Overall, GLP-1s are getting cheaper, he added, because companies like Novo Nordisk and Eli Lilly, which makes GLP-1s Zepbound and Mounjaro, want to compete with the compounding market
For years, Medicare had been legally prohibited from such dealmaking
Wegovy and Mounjaro are both weekly injections, but they work slightly differently
For any further questions, your UK online pharmacy or NHS Diabetes Service can provide up-to-date support and advice